Liposomal, nanoparticle, and conjugated formulations of anticancer agents

Clinical Cancer Research

Volumn 11, Issue 23, 2005, Pages 8230-8234

  Zamboni, William C ^a,b,c  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b Universigy of Pittsburgh   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; AMPHOTERICIN B LIPID COMPLEX; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BELOTECAN; CAMPTOTHECIN; CARBONIC ACID; CISPLATIN; CYTARABINE; DAUNORUBICIN; DOCOSAHEXAENOIC ACID; DOXORUBICIN; INTERFERON; IRINOTECAN; LIPOSOME; LURTOTECAN; MACROGOL; MACROGOL 40000; METHOTREXATE; NANOPARTICLE; PACLIMER; PACLITAXEL; PACLITAXEL POLIGLUMEX; TOPOTECAN; UNCLASSIFIED DRUG; VINCRISTINE;

CARDIOMYOPATHY; CARDIOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG FORMULATION; HUMAN; KERATOPATHY; MUCOSA INFLAMMATION; PRIORITY JOURNAL; REVIEW; SENSORY NEUROPATHY;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; LIPOSOMES; MICROSPHERES; NEOPLASMS;

EID: 28544446829     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1895     Document Type: Review

References (68)

1. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 1999;51:691-743.
2. Papahadjopoulos D, Allen TM, Gabizon A, et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci U S A 1991;88:11460-4.
3. Adis International Limited. ABI 007. Drugs R D 2004; 5:155-9.
4. Markman M, Gordon AN, McGuire WP, Muggia FM. Liposomal anthracycline treatment for ovarian cancer. Semin Oncol 2004;31:91-105.
5. Krown SE, Northfelt DW, Osoba D, Stewart JS. Use of liposomal anthracyclines in Kaposi's sarcoma. Semin Oncol 2004;31:36-52.
6. Abraxane package insert. 2005.
7. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000; 65:271-84.
8. Abraham SA, McKenzie C, Masin D, et al. In vitro and in vivo characterization of doxorubicin and vincristine coencapsulated within liposomes through use of transition metal ion complexation and pH gradient loading. Clin Cancer Res 2004;10:728-38.
9. Park JW, Benz CC, Martin FJ. Future directions of liposome- and immunoliposome-based cancer therapeutics. Semin Oncol 2004;31:196-205.
10. Laginha K, Mumbengegwi D, Allen T. Liposomes targeted via two different antibodies: assay, B-cell binding and cytotoxicity. Biochim Biophys Acta 2005;1711:25-32.
11. Zamboni WC, Gervais AC, Egorin MJ, et al. Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma. Cancer Chemother Pharmacol 2004;53:329-36.
12. Laverman P, Carstens MG, Boerman OC, et al. Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection. J Pharmacol Exp Ther 2001;298:607-12.
13. Litzinger DC, Buiting AM, van Rooijen N, Huang L. Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes. Biochim Biophys Acta 1994;1190:99-107.
14. Woodle MC, Lasic DD. Sterically stabilized liposomes. Biochim Biophys Acta 1992;1113:171-99.
15. Lasic DD, Frederik PM, Stuart MC, Barenholz Y, McIntosh TJ. Gelation of liposome interior. A novel method for drug encapsulation. FEBS Lett 1992;312: 255-8.
16. Barenholz Y. Relevancy of drug loading to liposomal formulation therapeutic efficacy. J Liposome Res 2003;13(1):1-8.
17. Allen TM, Hansen C. Pharmacokinetics of stealth versus conventional liposomes: effect of dose. Biochim Biophys Acta 1991;1068:133-41.
18. Allen TM, Stuart DD. Liposomal pharmacokinetics. Classical, sterically-stabilized, cationic liposomes and immunoliposomes. In: Janoff AS, editor. Liposomes: rational design. New York: Marcel Dekker, Inc.; 2005. p. 63-87.
19. Working PK, Newman MS, Stuart Y, et al. Pharmacokinetics, biodistribution and therapeutic efficacy of doxorubicin encapsulated in STEALTH liposomes. J Liposome Res 1994;46:667-87.
20. Newman MS, Colbern GT, Working PK, Engbers C, Amantea MA. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother Pharmacol 1999;43:1-7.
21. Allen TM, Martin FJ. Advantages of liposomal delivery systems for anthracyclines. Semin Oncol 2004;31:5-15.
22. Mori A, Klibanov AL, Torchilin VP, Huang L. Influence of the steric barrier activity of amphipathic poly(ethyleneglycol) and ganglioside GM1 on the circulation time of liposomes and on the target binding of immunoliposomes in vivo. FEBS Lett 1991;284:263-6.
23. Jain RK. Delivery of molecular medicine to solid tumors. Science 1996;271:1079-80.
24. Zamboni WC, Houghton PJ, Hulstein JL, et al. Relationship between tumor extracellular fluid exposure to topotecan and tumor response in human neuroblastoma xenograft and cell lines. Cancer Chemother Pharmacol 1999;43:269-76.
25. Harrington KJ, Mohammadtaghi S, Uster PS, et al. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res 2001;7:243-54.
26. 111In-DTPA-labelled pegylated liposomes in a human tumour xenograft model: implications for novel targeting strategies. Br J Cancer 2000;83:232-8.
27. Harrington KJ, Rowlinson-Busza G, Syrigos KN, et al. Influence of tumour size on uptake of (111)In-DTPA-labelled pegylated liposomes in a human tumour xenograft model. Br J Cancer 2000; 83:684-8.
28. Kim ES, Lu C, Khuri FR, et al. A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer. Lung Cancer 2001;34: 427-32.
29. Harrington KJ, Lewanski CR, Northcote AD, et al. Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer. Ann Oncol 2001;12:493-6.
30. Veerareddy PR, Vobalaboina V. Lipid-based formulations of amphotericin B. Drugs Today (Barc) 2004;40: 133-45.
31. Ewer MS, Martin FJ, Henderson C, Shapiro CL, Benjamin RS, Gabizon AA. Cardiac safety of liposomal anthracyclines. Semin Oncol 2004;31:161-81.
32. Northfelt DW. STEALTH liposomal doxorubicin (SLD) delivers more DOX to AIDS-Kaposi's sarcoma lesions than to normal skin. Proc Am Soc Oncol 1994; 13:51.
33. Berry G, Billingham M, Alderman E, et al. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. Ann Oncol 1998;9: 711-6.
34. Rose PG. Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer. Oncologist 2005;10:205-14.
35. Cattel L, Ceruti M, Dosio F. From conventional to stealth liposomes: a new frontier in cancer chemotherapy. J Chemother 2004;16 Suppl 4:94-7.
36. Vail DM, Amantea MA, Colbern GT, Martin FJ, Hilger RA, Working PK. Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies. Semin Oncol 2004;31: 16-35.
37. Kraut EH, Fishman MN, LoRusso PM, et al. Final results of a phase I study of liposome encapsulated SN-38 (LE-SN38): safety, pharmacogenomics, pharmacokinetics, and tumor response. Proc Am Soc Clin Oncol 2005;23:139s.
38. Lei S, Chien PY, Sheikh S, Zhang A, Ali S, Ahmad I. Enhanced therapeutic efficacy of a novel liposome-based formulation of SN-38 against human tumor models in SCID mice. Anticancer Drugs 2004;15: 773-8.
39. Pal A, Khan S, Wang YF, et al. Preclinical safety, pharmacokinetics and antitumor efficacy profile of liposome-entrapped SN-38 formulation. Anticancer Res 2005;25:331-41.
40. Zhang JA, Xuan T, Parmar M, et al. Development and characterization of a novel liposome-based formulation of SN-38. Int J Pharm 2004;270:93-107
41. Dark GG, Calvert AH, Grimshaw R, et al. Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the National Cancer Institute of Canada clinical trials group. J Clin Oncol 2005;23:1859-66.
42. Giles FJ, Tallman MS, Garcia-Manero G, et al. Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase I inhibitor, in patients with advanced leukemia. Cancer 2004;100:1449-58.
43. Kehrer DF, Bos AM, Verweij J, et al. Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicity. J Clin Oncol 2002;20:1222-31.
44. Gelmon K, Hirte H, Fisher B, et al. A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers. Invest New Drugs 2004;22:263-75.
45. Verschraegen CF, Gilbert BE, Loyer E, et al. Clinical evaluation of the delivery and safety of aerosolized liposomal 9-nitro-20(s)-camptothecin in patients with advanced pulmonary malignancies. Clin Cancer Res 2004;10:2319-26.
46. Knight V, Koshkina NV, Waldrep JC, Giovanella BC, Gilbert BE. Anticancer effect of 9-nitrocamptothecin liposome aerosol on human cancer xenografts in nude mice. Cancer Chemother Pharmacol 1999;44: 177-86.
47. Koshkina NV, Gilbert BE, Waldrep JC, Seryshev A, Knight V. Distribution of camptothecin after delivery as a liposome aerosol or following intramuscular injection in mice. Cancer Chemother Pharmacol 1999;44: 187-92.
48. Messerer CL, Ramsay EC, Waterhouse D, et al. Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer. Clin Cancer Res 2004;10: 6638-49.
49. Drummond DC, Noble CO, Guo Z, et al. Development of a highly stable liposomal irininotecan with low toxicity and potent antitumor efficacy. Proc AACR 2005;46:330.
50. Zamboni WC, Ramalingam S, Friedland DM, et al. Phase I and pharmacokinetic (PK) study of STEALTH liposomal CKD-602 (S-CKD602) in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2005; 23:152s.
51. Damajanov N, Fishman MN, Steinberg JL, et al. Final results of a Phase I study of liposome entrapped paclitaxel (LEP-ETU) in patients with advanced cancer. Proc Am Soc Clin Oncol 2005;23:147s.
52. Petros W, Dewhirst M, Poulson J, et al. Phase I and pharmacokinetic evaluation of a doxorubicin-containing low thermosensitive liposome in dogs with solid tumors. Proc AACR 2005;46:327, no. 1398.
53. Johnstone S, Harvie P, Shew C, et al. Synergistic antitumor activity observed for a fixed ratio liposome formulation of cytarabine (Cyt):daunorubicin (Daun) against preclinical leukemia models. Proc AACR 2005;46:9.
54. Ibrahim NK, Desai N, Legha S, et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 2002;8:1038-44.
55. Takimoto CH, Schwartz G, Romero O, et al. Phase I evaluation of paclitaxel poliglumex (PPX) administered weekly for patients with advanced cancer. Proc Am Soc Clin Oncol 2005;23:145s.
56. Dordunoo SK, Vineck W, Hoover R, Dang W. Sustained release of paclitaxel from PACLIMER® microspheres. Proc AACR 2005;46:985.
57. Bradley MO, Swindell CS, Anthony FH, et al. Tumor targeting by conjugation of DHA to paclitaxel. J Control Release 2001;74:233-6.
58. Wolff AC, Donehower RC, Carducci MK, et al. Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile. Clin Cancer Res 2003;9: 3589-97.
59. Greenwald RB. PEG drugs: an overview. J Control Release 2001;74:159-71.
60. Andersson L, Davies J, Duncan R, et al. Poly(ethylene glycol)-poly(ester-carbonate) block copolymers carrying PEG-peptidyl-doxorubicin pendant side chains: synthesis and evaluation as anticancer conjugates. Biomacromolecules 2005;6:914-26.
61. Riebeseel K, Biedermann E, Loser R, et al. Polyethylene glycol conjugates of methotrexate varying in their molecular weight from MW 750 to MW 40000: synthesis, characterization, and structure-activity relationships In vitro and in vivo. Bioconjug Chem 2002; 13:773-85.
62. Derbala M, Amer A, Bener A, Lopez AC, Omar M, El Ghannam M. Pegylated interferon-α 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis. J Viral Hepat 2005;12:380-5.
63. Castells L, Vargas V, Allende H, et al. Combined treatment with pegylated interferon (α-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol 2005;43: 53-9.
64. Paranjpe PV, Chen Y, Kholodovych V, Welsh W, Stein S, Sinko PJ. Tumor-targeted bioconjugate based delivery of camptothecin: design, synthesis and in vitro evaluation. J Control Release 2004;100:275-92.
65. Rowinsky EK, Rizzo J, Ochoa L, et al. A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies. J Clin Oncol 2003;21: 148-57.
66. de Groot FM, Busscher GF, Aben RW, Scheeren HW. Novel 20-carbonate linked prodrugs of camptothecin and 9-aminocamptothecin designed for activation by tumour-associated plasmin. Bioorg Med Chem Lett 2002;12:2371-6.
67. Papahadjopoulos D, Kirpotin DB, Park JW, et al. Targetting of drugs to solid tumors using anti-HER2 immunoliposomes. J Liposomes Res 1999;8: 425-42.
68. Zamboni WC, Whitner H, Potter DM, et al. Allometric scaling of STEALTH® liposomal anticancer agents. Proc AACR 2005;46:326.